Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule

Article

Abstract: We previously reported that CIMAvax-EGF vaccine is safe, immunogenic and efficacious to treat advanc

Palabras claves:

antibodies affinity, cancer vaccine, EGF, NSCLC, surrogate biomarker

Autores:

Alvarez K., Carmen Elena Viada, Fuentes K.P., García Verdecia B., González A., Gonzalez Z., Huerta V., Mazorra Z., Neninger Vinageras E., Popa X., Rodríguez P.C., Tania Crombet

Fuentes:

scopus